Compare PBHC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | NTHI |
|---|---|---|
| Founded | 1859 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 109.5M |
| IPO Year | 2014 | 2023 |
| Metric | PBHC | NTHI |
|---|---|---|
| Price | $16.27 | $4.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 4.6K | ★ 180.6K |
| Earning Date | 04-29-2026 | 05-19-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 46.25 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.06 | $3.01 |
| 52 Week High | $17.40 | $12.99 |
| Indicator | PBHC | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 54.63 |
| Support Level | $15.50 | $3.01 |
| Resistance Level | $17.14 | $4.59 |
| Average True Range (ATR) | 0.34 | 0.44 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 45.71 | 58.70 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.